ライフサイエンスコーパス: be experienced by

1 very 700 births; major obstetric haemorrhage is experienced by 1 in 172 women; cases of eclampsia hav

2 te and life-threatening respiratory symptoms are experienced by 10-20% of symptomatic patients, parti

3 spondents, and honorary authorship practices were experienced by 100 (39.4%) respondents.

4 AMPT-induced return of depressive symptoms was experienced by 11 of the 18 patients and led to decr

5 Severe exacerbations were experienced by 11% of the patients in IRF groups an

6 We found that at least one atypical transfer was experienced by 12.9% of patients.

7 Psychological violence was experienced by 12.9% of the participants, while 5.3%

8 Severe anaphylaxis was experienced by 12/46 (26%) and mild-moderate anaphyl

9 ally meaningful improvement in PTSD symptoms was experienced by 120 (28.3%) of the 424 patients seen

10 98], P = .03).Persistent mobility disability was experienced by 120 participants (14.7%) in the physi

11 by patients and/or families in the past year was experienced by 143 (53% overall: 67% of women, 35% o

12 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20

13 Anaphylaxis was experienced by 18% and shock by 7.1%.

14 At least one privation was experienced by 18% of the sample; blacks (OR, 2.6; P

15 Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5;

16 Negative consequences were experienced by 18.3% of participants with disabilit

17 Early ICU readmission and death was experienced by 2.54% and 0.92% of all patients, resp

18 Poor recovery was experienced by 21.4%, 52.0% of whom had died.

19 Allocation challenges were experienced by 21 OPOs (43%); their median (range)

20 (first HF-related hospitalization or death) was experienced by 22 (24%) in the intervention group an

21 Grade 4 thrombocytopenia was experienced by 22.1% of patients in 5.1% of courses.

22 Clinical benefit response was experienced by 23.8% of gemcitabine-treated patients

23 ong 5269 participants, cardiovascular events were experienced by 251 (8.9%) of 2823 patients taking a

24 its; however, mild sensory symptoms or signs were experienced by 27 patients; 'prickling' or 'asleep

25 Grade 3 or 4 anemia was experienced by 29.2% of patients in 8.5% of courses.

26 Excluding pouchitis, late complications were experienced by 29.1% of patients.

27 Racial/ethnic microaggressions were experienced by 299 of 367 racial/ethnic-minority ph

28 SCE was experienced by 3.5% (n = 109) over a median follow-u

29 t least one treatment-emergent adverse event was experienced by 30-36% of participants in each group.

30 Treatment-emergent AEs were experienced by 32.8% (106/323), 39.8% (43/108), and

31 Treatment nonsuccess was experienced by 33% (ODI), 27% (NRS back pain), and 3

32 Pain was experienced by 34 (81%) patients, dry eyes by 32 (76

33 Serious or life-threatening toxicity was experienced by 34%, with asthenia (15%) and neuropsy

34 Negative discrimination was experienced by 344 (47%) of 729 participants in maki

35 Serious adverse events were experienced by 35 (18%) patients in the olaparib gr

36 Chronic severe pain was experienced by 37% of MMTP patients (95% confidence

37 Declines in MRI-PDFF of >=30% were experienced by 39% of patients receiving cilofexor

38 associated treatment-limiting adverse events were experienced by 41% of the patients.

39 'Worry about falling' was experienced by 42.0% (128/305) of fallers, 'loss of

40 53 serious adverse events (SAEs) were experienced by 42 (4.5%) of 930 girls, the most com

41 Grade 3/4 adverse events were experienced by 43% of patients.

42 r 4 treatment-related adverse events (TRAEs) were experienced by 43%, 67%, 57%, and 45% of patients,

43 treatment-emergent adverse events grade >=3 were experienced by 43.2% of patients with BMs and 46.4%

44 azithromycin group, 473; placebo group, 464) were experienced by 443 children (azithromycin group, 22

45 Adverse events were experienced by 46 (57%) of 81 patients in the ALD40

46 CRTs were experienced by 46% of patients on T-DM1 and 47% of

47 Nausea and vomiting were experienced by 47.0% of all physostigmine-treated s

48 neutropenia, thrombocytopenia, and mucositis were experienced by 48 (92%), 46 (88%), and 10 (19%) pat

49 Grade 4 neutropenia was experienced by 50.4% of patients in 13.4% of courses

50 vents related to the gastrointestinal system were experienced by 50.2% and 39.2% of patients in the l

51 School suspension was experienced by 504 autistic students (5.2%) and 13 8

52 TEAEs were experienced by 52 (81%) of 64 patients treated with

53 The primary outcome, acute hyponatremia, was experienced by 53% of 68 participants in the Plasma-

54 Mild traumatic brain injury (TBI) is experienced by 55.9 million people globally each year

55 only or CD8a depletion only, on-ART viremia was experienced by 56% and 57% of the animals respective

56 Suspensions were experienced by 57 autistic students (2.0%) with hig

57 ognitive problems 1 year after ICU admission were experienced by 58% of the medical patients, 64% of

58 CTCAE v4 grade 3 adverse events were experienced by 62% of patients in the experimental

59 CTCAE v4 grade >=3 adverse events were experienced by 62% of patients in the experimental

60 Grade 3 or 4 neutropenia was experienced by 66% of patients, with more events in

61 >=3 treatment-related adverse events (TRAEs) were experienced by 72% of patients.

62 Negative attitudes towards JDs were experienced by 82% (nine of 11) of JDs, including b

63 Hundred erosions were experienced by 85 patients (2.85%) at a median time

64 On-study SREs were experienced by 9% of denosumab-treated patients (20

65 At least one PPTR event was experienced by 92.4% (133 of 144) of participants wi

66 A first non-fatal stroke was experienced by 9265 (2.8%) women and 4003 (0.7%) exp

67 Incident unemployment was experienced by 944 (33.2%) and incident work disabil

68 rstanding of how the molecular tensions that are experienced by a particular protein affect the recru

69 Continued long-term immunologic benefit may be experienced by a subset of children, despite only tra

70 (13.3%), conversion (2.2%), and leaks (5.8%) were experienced by a total of 22 patients (18.3%).

71 ones fluctuations across the menstrual cycle are experienced by about 58% of women in their fertile a

72 ated that longer times to hormone initiation were experienced by adolescents aged 14 to 16 years (IRR

73 se rapidly, such that the same concentration is experienced by all bacteria.

74 significant decline in cognitive functioning was experienced by all types of patients.

75 elevations in plasma CORT levels (eg, as may be experienced by an individual during stressful episode

76 on and hospital readmission for dehydration, are experienced by approximately 15% and 8% of patients,

77 Further, these data suggest that haem stress is experienced by bacterial pathogens during infection.

78 the stress of a sustained inflammation that is experienced by Fancc(-/-) mice.

79 onate burden of infectious diseases that can be experienced by First Nations peoples.

80 n group, respectively; in APPOINT-PNH, these were experienced by four (10%) and eight (20%) of 40 pat

81 oxicities (gastrointestinal events and rash) were experienced by four patients.

82 t little is known about how these conditions were experienced by frontline clinicians.

83 the intensity of one kind of selection that is experienced by genes and can be used to assess the im

84 ber pressures, and tissue strains that could be experienced by implanted cardiac tissues.

85 Instead, gravitational forces may be experienced by individual cells in the living organis

86 marker of peak emotional-hedonic responses, are experienced by individuals across a variety of human

87 lifelong impairment in face recognition that is experienced by individuals who suffer from congenital

88 This presupposes which events are experienced by infants and leaves open questions abo

89 Acute electrolyte and acid-base imbalance is experienced by many children following kidney transpl

90 Although pain is experienced by many patients with diabetic neuropathy

91 otor symptoms (hot flushes and night sweats) are experienced by more than two-thirds of women with br

92 W events, we show similar lethal effects can be experienced by more common but neglected acute marine

93 y intense itching, but concomitant skin pain is experienced by more than 40% of patients.

94 e demonstrate that these metabolic pressures are experienced by Mtb inside its host macrophage and th

95 Bereavement by 10 years of age was experienced by n = 796 (37.3%) of youth and was asso

96 Catastrophic costs were experienced by nine (47%) of 19 households who rece

97 Smaller losses were experienced by non-children's hospital teaching hos

98 dverse event was minor ear infections, which was experienced by one patient in the gentamicin group a

99 However, these outcomes are experienced by only a minority of patients with LGE,

100 ty reduction has occurred since 1900 and has been experienced by only about 4 of the roughly 8,000 hu

101 lation, the growth benefit from phycospheres is experienced by only a small fraction of cells.

102 ithout the radical evolutionary changes that are experienced by other species, suggesting that specie

103 Understanding how the Navigate-Kidney trial was experienced by participants is important when consid

104 tra 3000 MACEs, including nearly 600 deaths, were experienced by participants not treated with statin

105 fficult emotions and other forms of distress are experienced by patients and families during ICU deli

106 addition, the poor physical functioning that is experienced by patients who are on dialysis is potent

107 ary and several extrapulmonary organ systems is experienced by patients who survive after the acute p

108 ection: when dry, cold, and hot environments were experienced by seedlings, selection was intensified

109 Stable disease was experienced by seven patients for 11 to 18 weeks.

110 nd serious treatment-emergent adverse events were experienced by six (10%) and nine (15%) of 62 patie

111 opportunities to achieve optimal health that are experienced by socially disadvantaged population gro

112 when plausibly avoidable health differences are experienced by socially disadvantaged populations.

113 shows acute muscle wasting and weakness and is experienced by some patients with severe systemic ill

114 ible salivary gland disease and oral dryness is experienced by sufferers of Sjogren's syndrome and th

115 conditions-due to artificial light exposure-are experienced by the majority of the populace on a dai

116 y a motivational role, however, they need to be experienced by the organism.

117 atial locations where the perturbations have been experienced by the moving arm.

118 This force is experienced by the cells inside the cell medium, and

119 Adverse events were experienced by the majority of patients, but estima

120 As a consequence, more YPLL before age 65 were experienced by the NHB and Hispanic populations tha

121 esthesia for either treatment, although pain was experienced by these patients in 46.8% of the contro

122 icity was enhanced at cool temperatures that are experienced by this organism in its natural habitat.

123 We also cover how these effects are experienced by those in marginalized communities, in

124 important reduction in hospitalization rates is experienced by transplanted patients.

125 d cancer-related cognitive impairment (CRCI) are experienced by up to 26% of individuals diagnosed wi